Evidence map›Paper›PMID 29956808›Full record

ArticleOncology reports2018

Inhibition of RAD54B suppresses proliferation and promotes apoptosis in hepatoma cells.

Rui Wang, Yawei Li, Yufo Chen, Lei Wang, Qiong Wu, Yuanyuan Guo, Yumei Li, Jing Liu, Liwei Wang

Open access · hybridAbstract read
In one paragraph

Article in Oncology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Japonicone A and related dimeric sesquiterpene lactones: molecular targets and mechanisms of anticancer activity.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022
    Review
  5. Article
  6. Article
  7. Article
  8. Association betweenAvicenna journal of medical biotechnology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Rui WangDepartment of Oncology, Shanghai General Hospital of Nanjing Medical University, Shanghai 201620, P.R. China.
Yawei LiDepartment of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, P.R. China.
Yufo ChenDepartment of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, P.R. China.
Lei WangDepartment of Oncology, Shanghai General Hospital of Nanjing Medical University, Shanghai 201620, P.R. China.
Qiong WuDepartment of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, P.R. China.
Yuanyuan GuoDepartment of Urology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, P.R. China.
Yumei LiDepartment of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, P.R. China.
Jing LiuDepartment of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, P.R. China.
Liwei WangDepartment of Oncology, Shanghai General Hospital of Nanjing Medical University, Shanghai 201620, P.R. China.
First Affiliated Hospital of Bengbu Medical College · CNNanjing Medical University · CNShanghai First People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RAD54 homolog B is a central motor protein of homologous recombination (HR), which plays an important role in the development and evolution of human cancer. Recent studies have indicated that RAD54B is aberrantly expressed in a variety of cancers and exhibits numerous biological functions, including participating in the repair of DNA double strand breaks. However, the expression and function of RAD54B in liver cancer have not yet been reported. The aim of the present study was to investigate the expression of RAD54B and elucidate its role in liver cancer cell lines by inhibiting RAD54B using a lentivirus-mediated shRNA interference system. We also assessed the effect of RAD54B on cell proliferation, colony formation, cell cycle distribution and cell apoptosis in BEL-7404 and SMMC-7721 cell lines using shRAD54B or shCtrl transfection. Furthermore, we analyzed the relationship between the expression of RAD54B protein, as measured by immunohistochemical staining, and the prognosis of patients with hepatoma. We found that RAD54B was highly expressed in liver cancer cell lines compared with the normal hepatic cell line LO2. Similarly, positive expression of RAD54B, which is associated with poor prognosis, was also observed in 52/83 samples of liver cancer tissue. Additionally, RAD54B downregulation significantly inhibited cell proliferation and colony formation, while also inducing G1/S cell cycle arrest and apoptosis in BEL-7404 and SMMC-7721 cells. These results indicated that RAD54B has oncogenic properties, and may be a potential treatment target for liver cancer patients.

Indexed as

ApoptosisCell ProliferationGene Expression Regulation, NeoplasticBiomarkers, TumorCarcinoma, HepatocellularCase-Control StudiesDNA HelicasesFollow-Up StudiesHumansLiver NeoplasmsNuclear ProteinsPrognosisRNA, Small InterferingTumor Cells, CulturedBiomarkers, TumorDNA HelicasesNuclear ProteinsRAD54B protein, humanRNA, Small Interfering

Identifiers

PMID29956808
PMCPMC6072389
OpenAlexW2810126669

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.